ClinicalTrials.gg
CompletedNCT00963443Updated Dec 5, 2014

Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold

A Phase 3 interventional study of Acetylsalicylic Acid (Aspirin, BAYE4465) and Pseudoephedrine in Common Cold, sponsored by Bayer. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-05.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
833
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Common Cold with a site in United Kingdom — none open to participants now, 1 under way, none of them phase 3. Common Cold · United Kingdom.

Enrollment
Largest of 20
833 · median 89
Started
2009
the only one that year
Phase 3
4 of 20
none open now
Registered
3rd of 20
by date
Lead sponsor
2 of 20
Bayer

Among the 20 studies in Common Cold with a site in United Kingdom, this one has the largest enrollment, is the only one that started in 2009, is one of 4 in phase 3, and was the 3rd registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

None of the 20 studies in Common Cold with a site in United Kingdom is open now. The open studies under Common Cold, anywhere →

Who these studies take

Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Common Cold with a site in United Kingdom as a file.
02

Study summary

The purpose of the study is to determine the effectiveness of an acetylsalicylic acid (aspirin) pseudoephedrine combination for the treatment of pain and congestion symptoms compared to the effectiveness of the individual components of the medicine and the placebo (dummy treatment that looks like the real thing).The combination product of acetylsalicylic acid / pseudoephedrine is already marketed in several European countries as Aspirin® Complex.

03

Conditions studied

  • Common Cold

Browse trials for

Keywords

  • Aspirin Complex
  • Acetylsalicylic Acid
  • Pseudoephedrine
  • Common Cold
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient in general good health with suspected viral upper respiratory tract infection (common cold)

Exclusion criteria

Exclusion Criteria:

  • \< 18 years old
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
833 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Acetylsalicylic Acid (Aspirin, BAYE4465) · Drug: Pseudoephedrine

  • Active comparator
    Arm 2

    Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

  • Active comparator
    Arm 3

    Drug: Pseudoephedrine

  • Placebo comparator
    Arm 4

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Reduction of nasal congestion and relief of pain

    Time frame: 4 hours

Secondary outcomes

  1. Area under the curve for nasal airflow conductance from baseline

    Time frame: 1h, 2h, 3h

  2. Sum of subjective nasal congestion intensity differences

    Time frame: 1h, 2h, 3h, 4h and 1, 2, 3 days

  3. Total subjective nasal congestion relief

    Time frame: 1h, 2h, 3h,4 h and 1, 2, 3 days

  4. Global assessment of nasal congestion

    Time frame: 3 days

  5. Global assessment of pain relief

    Time frame: 3 days

  6. Sum of pain intensity differences

    Time frame: 1h, 2h, 3h, 4h and 1, 2, 3 days

  7. Total pain relief

    Time frame: 1, 2, 3 days

  8. Adverse Event collection and physical examination

    Time frame: 3 days

07

Study locations

1 site
  • Cardiff, South Glamorgan CF1 3US, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2009
First posted
Aug 21, 2009
Start
Sep 2009
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Last update
Dec 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00963443
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Aug 21, 2009
Start date
Sep 2009
Primary completion
Mar 2012
Completion
Mar 2012
Last update
Dec 5, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Pseudoephedrine

Start the discussion